| Field | Specification |
|---|---|
| Applications | |
| Serotype | Multiple (selectable) |
| Transgene | |
| Promoter | |
| Expression regulation | |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
CRISPR sgRNA Control Vector
Constitutive expression of CRE driven by the U6 + CAG (dual) promoter.
Research background
This AAV provides recombinase-based genetic access, enabling conditional control of downstream payloads in genetically defined cells. Recombinase tools are widely used to restrict expression, create intersectional logic, or enable lineage/cell-type targeting.
Mechanism and expected readouts
Recombinase expression catalyzes site-specific DNA recombination at matching target sites, permanently switching genetic states in infected cells. This can gate expression of FLEX/DIO payloads or enable intersectional strategies when combined with other recombinases.
Expression design and interpretation
Expression is driven by the U6 + CAG (dual) promoter, which determines where and how strongly the payload is expressed in your system (dual-promoter design — U6 (Pol III) transcribes the sgRNA; CAG (Pol II) drives the protein cassette in broad mammalian cell types). The construct's regulatory logic controls where/when the payload is active; expression is constitutive (no recombinase or inducer required). The encoded payload is intended to support the stated experimental function (e.g., modulation, sensing, labeling, or control). Two independent transcription units operate here: U6 is a compact RNA polymerase III promoter optimized for short, non-polyadenylated transcripts such as guide RNAs, while CAG is an RNA polymerase II promoter giving strong protein-level expression of the reporter. Because the guide is a scramble/non-targeting control, the vector reproduces the non-specific effects of sgRNA expression and AAV transduction without acting on a target gene.
Subcellular targeting elements (when present) can bias localization and should be confirmed by imaging in your preparation.
Common research applications
- Conditional targeting for cell-type or projection-specific experiments
- Intersectional labeling or manipulation strategies
- Permanent genetic switching for lineage or fate-mapping workflows
Experimental considerations
- Verify recombination efficiency with a compatible reporter in your system
- Account for irreversible switching when designing longitudinal studies
- Use appropriate negative controls (no recombinase or mismatched recombinase lines)
Controls and validation
Typical validation includes confirming expression pattern and level, verifying functional activity with an assay matched to the payload (e.g., imaging, electrophysiology, pharmacology, or behavior), and using appropriate negative controls.
At present, the main purification approaches for rAAV include:
- Ultracentrifugation density-gradient methods, using cesium chloride (CsCl) or iodixanol as the gradient medium;
- Chemical reagent precipitation/extraction methods, mainly using PEG, ammonium sulfate, chloroform, etc.;
- Chromatographic purification methods, primarily based on affinity and ion-exchange principles.
Depending on customers’ different application needs, we can integrate multiple methods to produce high-titer, high-purity, high-quality rAAV viral products.
Can’t find the AAV you need—or require a custom design and packaging service? We offer end-to-end support for diverse research and therapeutic needs, including vector design and cloning, AAV packaging services (serotype/capsid selection and production), QC & characterization (project-appropriate testing and documentation), and library preparation for pooled or library-style workflows (project dependent). Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
